Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7CI9P
|
|||
| Drug Name |
BI 894416
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 1 | [1] | |
| Company |
Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03971539) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 894416 Versus Placebo in Male Patients With Asthma (Single-blind, Randomised, Placebo-controlled, Parallel Group Design). U.S.National Institutes of Health. | |||
| REF 2 | Synthesis of BI 894416 and BI 1342561, two potent and selective spleen tyrosine kinase inhibitors, labeled with carbon 14 and with deuterium. J Labelled Comp Radiopharm. 2023 Apr-May;66(4-6):155-168. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.